Your session is about to expire
← Back to Search
Small Molecule Drug
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) for Non-Small Cell Lung Cancer
Phase 2
Waitlist Available
Led By Hossein Borghaei, DO
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
Study Summary
This trial is studying a new lung cancer drug to see if it shrinks tumors before surgery. Doctors will enroll 25 patients who have not had lung cancer treatment before and are healthy enough for surgery.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Major pathologic response
Secondary outcome measures
Determine the safety, feasibility and tolerability of neoadjuvant sotorasib therapy in patients with surgically resectable KRAS G12C mutant NSCLC
Trial Design
1Treatment groups
Experimental Treatment
Group I: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Fox Chase Cancer CenterLead Sponsor
229 Previous Clinical Trials
38,176 Total Patients Enrolled
Hossein Borghaei, DOPrincipal InvestigatorFox Chase Cancer Center
3 Previous Clinical Trials
93 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger